The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review
Open accessAbstract
INTRODUCTION: Generalized anxiety disorder (GAD) often begins during adolescence or early adulthood and persists throughout the lifespan. Randomized controlled trials support the efficacy of selective serotonin and selective serotonin norepinephrine reuptake inhibitors (SSRIs and SNRIs, respectively), as well as benzodiazepines, azapirones, anti-adrenergic medications, melatonin analogs, second-generation antipsychotics, kava, and lavender oil in GAD. However, psychopharmacologic treatment selection requires clinicians to consider multiple factors, including age, co-morbidity, and prior treatment. Areas covered: The authors review the literature concerning pharmacotherapy for pediatric and adult patients with GAD with specific commentary on the efficacy and tolerability of selected agents in these age groups. The authors describe an algorithmic approach to the pediatric and adult patient with GAD and highlight considerations for the use of selected medications in these patients. Expert opinion: In adults with GAD, SSRIs and SNRIs represent the first-line psychopharmacologic treatment while second-line pharmacotherapies include buspirone, benzodiazepines, SGAs, and pregabalin. In pediatric patients with GAD, SSRIs should be considered the first line pharmacotherapy and psychotherapy enhances antidepressant response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, research on these medications for this population is limited, and their use is generally not preferred over SSRIs and SNRIs and should only be used with great caution and close monitoring in this population because of the adverse side effect profile [31,34,35].”
From The risks versus the benefits of pharmacological intervention in social anxiety disorder in children (2025) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second-line treatments include serotonin-norepinephrine reuptake inhibitors (SNRIs) [31,32].”
From The risks versus the benefits of pharmacological intervention in social anxiety disorder in children (2025) · cites this paper as [31]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Pine, D. S., Cohen, P., Gurley, D., Brook, J., & Ma, Y. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.1.56 · Cited by 1,753
Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety
Walkup, J. T., Albano, A. M., Piacentini, J., Birmaher, B., Compton, S. N., Sherrill, J. T., Ginsburg, G. S., Rynn, M. A., McCracken, J., Waslick, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804633 · Cited by 1,442
The therapeutic potential of monoamine oxidase inhibitors
Youdim, M. B. H., Edmondson, D. E., & Tipton, K. F. (2006) · Nature reviews. Neuroscience · doi:10.1038/nrn1883 · Cited by 1,401
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090 · cited 6×
“although guidelines and evidence suggest that – across age groups – SSRIs should be considered the first line interventions, followed by SNRIs [17,18].”
BackgroundMethodResultInfluentialRadioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P. M., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,061
Bruce, S. E., Yonkers, K. A., Otto, M. W., Eisen, J. L., Weisberg, R. B., Pagano, M., Shea, M. T., & Keller, M. B. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.6.1179 · Cited by 963
The global burden of anxiety disorders in 2010
Baxter, A. J., Vos, T., Scott, K. M., Ferrari, A. J., & Whiteford, H. A. (2014) · Psychological Medicine · doi:10.1017/s0033291713003243 · Cited by 768
Cipriani, A., Zhou, X., Del Giovane, C., Hetrick, S. E., Qin, B., Whittington, C., Coghill, D., Zhang, Y., Hazell, P., Leucht, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30385-3 · Cited by 734
Generalized anxiety disorder: prevalence, burden, and cost to society
Wittchen, H.-U. (2002) · Depression and Anxiety · doi:10.1002/da.10065 · Cited by 733
Research works printed but not linked: 22
- Nutt DJ, 2001, J. Clin. Psychiatry, 15
- 10.3109/10401230590932326 · DOI
- Beach SR, 2014, J. Clin. Psychiatry, 75(5):e441-9
- Sheehan DV, 2001, J. Clin. Psychiatry, 62, 26
- Orsolini L, 2016, Expert Rev. Neurother, 16(5):483–495
- Findling RL, 2017, J. Child Adolesc. Psychopharmacol
- Goddarda W, 2001, Arch. Gen. Psychiatry
- Seedat S, 2004, J. Clin. Psychiatry, 65, 244
- Feighner JP, 1999, J. Clin. Psychiatry, 4
- Hoehn-Saric R, 1988, J. Clin. Psychiatry, 49, 293
- Chessick CA, 2006, Cochrane Database Syst. Rev, CD006115
- Guaiana G, 2010, Cochrane Database Syst. Rev
- Schaller JL, 2004, MedGenMed, 6, 8
- Schwartz TL, 2002, Psychopharmacol. Bull, 36, 53
- Kassahun K, 1997, Drug Metab. Dispos, 25, 81
- Guy W, 1976, ECDEU Assess. Man, 217
- Lieberman JA, 2004, Am Psychiatr Publishing Textbook, 487
- Hoge EA, 2008, CNS Spectr, 13(6):522–527
- Möller HJ, Eur. Arch. Psychiatry Clin. Neurosci
- Pittler MH, Cochrane Database Syst. Rev
- Wang Z, 2017, JAMA Pediatr, 171
- Cipriani A, 2016, Lancet
Cited by
Sorted by citations
Items 201–213 of 213
Alves, B. C. M., Yamamoto, P. A., Souza, C. D. S., Lanchote, V. L., Rocha, A., de Moraes, N. V., & Godoy, A. L. P. C. (2026) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70194
Holopainen, A. K., Vainiotalo, P. A., Arrhenius, B., Ringbom, I., Laurila, M., & Gyllenberg, D. (2026) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-026-03049-9
The Role of Rumination as a Maladaptive Coping Mechanism in Cases of Comprehensive Anxiety Disorder
Firlani, O. A., Algristian, H., & Cahyono, B. (2026) · Psychosocia Journal of Applied Psychology and Social Psychology · doi:10.61978/psychosocia.v4i2.1376
Dunalska, A., Jakubczyk, A., Szulc, A., & Szejko, N. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-08225-4
Rashid, M. H. B., Islam, M., Islam, S. M. A., & Islam, M. R. (2026) · Experimental Biology and Medicine · doi:10.3389/ebm.2026.11144
Antipsychotics in Anxiety Disorders and Obsessive-compulsive Disorder in Children and Adolescents
Rajalakshmi, A. K., & Greenberg, E. (2026) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2026.07.005
Exploring the Anti-Anxiety and Anti-Convulsant Effects of Royal Jelly in Mice
Fischer, D., & Braun, T. (2023) · Journal of Applied Pharmaceutical Technologies and Systems · doi:10.68159/l228232637
Li, S., Lo, L. L. H., Lau, C., Lam, M., & Chan, M. (2026) · JMIR mhealth and uhealth · doi:10.2196/72435
The influence of working memory on the relationship between anxiety and reinforcement learning
Pereira, P. A., Núñez-Estupiñán, H. X., Weydmann, G. J., & Bizarro, L. (2026) · Learning and Motivation · doi:10.1016/j.lmot.2026.102346
Cubała, W. J. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2744754
Li, W., Wang, G., Manoharan, P., Cui, X., Dai, L., & Huang, L. (2026) · PLoS ONE · doi:10.1371/journal.pone.0360478
Increased Serum TNF‐α Levels Are Associated With Generalized Anxiety Disorder: A Case‐Control Study
Nur, T. A., Ahmed, Z. L., Emon, F. A., Urmi, T. J., Parves, M. M., Islam, M. R., & Nahar, Z. (2026) · Health Science Reports · doi:10.1002/hsr2.73277
Anggarany, A. D., & Kartika, E. (2025) · Journal Pharmaceutical Care and Sciences · doi:10.33859/jpcs.v6i1.881
Metadata
- Authors
- Strawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., & Levine, A.
- Affiliations
- University of Cincinnati (US)
- Columbia University (US)
- Corresponding author
- Strawn, Jeffrey R.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2018-07-03
- Volume
- 19
- Issue
- 10
- Pages
- 1057-1070
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- PMC
- PMC6340395
- OpenAlex
- W2884641336
- Cited by
- 214
- References
- 131
- Citations by year
- 2026: 18 · 2025: 27 · 2024: 38 · 2023: 50 · 2022: 33 · 2021: 23 · 2020: 21 · 2019: 2 · 2018: 2
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Expert Opinion on Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (K23MH106037)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Keywords
- generalized anxiety disorder, pharmacotherapy, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, benzodiazepines, buspirone, atypical antipsychotics, pregabalin, kava, lavender essential oil, childhood anxiety, adult anxiety, treatment selection algorithm, treatment efficacy and tolerability, psychotherapy
- MeSH terms
- Serotonin and Noradrenaline Reuptake Inhibitors, Adult, Antidepressive Agents, Anxiety Disorders, Child, Humans, Monoamine Oxidase Inhibitors, Antipsychotic Agents, Selective Serotonin Reuptake Inhibitors, Evidence-Based Practice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
